Genia

NEW YORK (GenomeWeb) – When Roche announced last month that it planned to acquire nanopore sequencing startup Genia for up to $350 million, unbeknownst to the public

NEW YORK (GenomeWeb) — Following its agreement with Pacific Biosciences last year to develop a sequencing platform for clinical diagnostics, Roche put its strategy for next-generation sequencing on a second leg this week by agreeing to acquire single-molecule nanopore sequencing startup Genia for

A team of collaborating researchers from Columbia University, Harvard Medical School, Genia, and the National Institute of Standards and Technology has shown proof of principle for a tag-based single-molecule nanopore sequencing approach they have been developing.

Last week, Base4 Innovation said it plans to collaborate with Hitachi to develop a solid-state nanopore sequencer.

A recent simulation study in the

By Julia Karow

By Bernadette Toner

This article was originally published Jan. 16.